I have no idea how on G-d’s green earth I missed this one. Courtesy of Google:
MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time
VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ – MannKind Corporation (Nasdaq: MNKD) will host a live broadcast to review clinical results from its final two Phase 3 studies of AFRESA™, the company’s ultra rapid acting, inhaled insulin product, at 9 a.m. Eastern Time on Thursday, December 18, 2008.
The results they released so far showed no pulmonary complications and equivalency to injected insulin (based on A1c), according to http://www.mannkindcorp.com/pressreleasetext.aspx?releaseID=1232470.
They plan to submit a new drug application to the FDA in early 2009.
(EDIT: For phase II results in T1s, see: http://www.genengnews.com/news/bnitem.aspx?name=580841)